Vifor Pharma: First patient enrolled in phase-IIa study of v

Vamifeport (VIT-2763) is the first oral ferroportin inhibitor investigated for treatment of diseases with ineffective production of red blood cells and iron overload such as sickle cell disease

Related Keywords

United States , United Kingdom , Switzerland , Greece , Lebanon , Swiss , Vifor Pharma , Julien Vignot , Klaus Henning Jensen , Nathalie Ponnier , Swiss Stock Exchange , Drug Administration , Global Head Corporate Communications , Swiss Exchange , Vifor Pharma Group , European Medicines Agency , Fresenius Medical Care , Chief Medical Officer , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , Head Corporate Communications , Investor Relations , Vifor , Dharma , First , Patient , Unrolled , Hase , Study , Amifeport , Patients , Pickle , Fell , Disease ,